Business
Site Visit Presentation
Site Visit Presentation.
About this update from Rhi Magnesita Nv
[{"type":"text","content":"\n \nRNS Number : 7318I RHI Magnesita N.V. 28 November 2018 \n\n \n \nRHI Magnesita N.V.\n(\"RHI Magnesita\" or the \"Company\")\n \n \nSite Visit Presentation\n \nRHI Magnesita N.V. (LSE: RHIM) is holding a site visit today for analysts and investors to its Leoben R&D Centre and Veitsch Plant in Austria. The presentation will be made available on the Company's website at: https://ir.rhimagnesita.com/investors/results-presentations/. \n \n \nFor further enquiries, please contact:\n \nGuy Marks, Head of Investor Relations\nTel +44 7741 730681\nE‐mail: [email protected]\n \nStefan Rathausky, Head of Corporate Communications\nTel +43 50213‐6059\nE‐mail: [email protected]\n \n \n \nAbout RHI Magnesita\n \nRHI Magnesita is the global leading supplier of high-grade refractory products, systems and services which are indispensable for industrial high-temperature processes exceeding 1,200°C in a wide range of industries, including steel, cement, non-ferrous metals, and glass, among others. With a vertically integrated value chain, from raw materials to refractory products and full performance-based solutions, RHI Magnesita serves more than 10,000 customers in nearly all countries around the world.\n \nThe Company has unmatched geographic diversification with more than 14,000 employees in 35 main production sites and more than 70 sales offices. RHI Magnesita intends to use its global leadership position in terms of revenue, greater scale, complementary product portfolio and diversified geographic presence around the world to target opportunistically those countries and regions benefitting from more dynamic economic growth prospects.\n \nIts shares have a premium listing on the London Stock Exchange (symbol: RHIM) and are a constituent of the FTSE 250 index. \n\nThis information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com. END MSCUWVNRWAAAURA\n ","length":4079,"tagName":"div"}]